Revenue Growth
MDT achieved an 8.7% increase in revenue, driven by strong sales across key segments.
Source: 10-Q Income Statement
Computed from published fixed rules, not a model's judgement — though one input, the count of high-severity risks, comes from the AI analysis below.
Not investment advice and not a price target: it scores the quarter's fundamentals, not the stock. Full methodology →
AI Takeaway
In Q3 FY2026, MDT reported a revenue increase of 8.7% but faced declining operating and net income due to rising costs, impacting margins and earnings per share.
Revenue
$9.02B
+8.74% YoY
EPS (Diluted)
$0.89
-11.88% YoY
Operating Income
$1.46B
-11.06% YoY
Source: SEC XBRL
Medtronic (MDT) reported Q3 FY2026 revenue of $9.02B, up 8.7% year over year. Operating margin was 16.2%, down 3.7 points from 19.9% a year earlier. MDT's fiscal Q3 FY2026 corresponds to calendar Q1 2026.
Last 4 quarters: 3 beats
| Quarter | Actual EPS (USD) | Consensus (USD) | Result |
|---|---|---|---|
| Sep 2026 | 1.45 | 1.40 | Beat +3.4% |
| Jun 2026 | 1.55 | 1.56 | Miss -0.4% |
| Mar 2026This filing | 1.36 | 1.35 | Beat +0.9% |
| Dec 2025 | 1.36 | 1.33 | Beat +2.4% |
Adjusted (non-GAAP) EPS of $1.36 versus the $1.35 analyst consensus — a +0.9% beat for Mar 2026. Analyst consensus is quoted on the adjusted (non-GAAP) basis the street uses. GAAP diluted EPS for this quarter was $0.89.
Compiled by AI from this SEC filing
MDT achieved an 8.7% increase in revenue, driven by strong sales across key segments.
Source: 10-Q Income Statement
The cost of revenue increased by 17.3%, significantly impacting operating income and margins.
Source: 10-Q Income Statement
Operating margin decreased to 16.2% from 19.9%, reflecting higher SG&A expenses and cost of revenue.
Source: 10-Q Key Ratios
Compiled by AI from this SEC filing · 1 high, 2 medium, 0 low
The company experienced a 17.3% increase in the cost of revenue, which could continue to pressure margins if inflation persists.
Source: 10-Q Income Statement
Share buybacks decreased by 79.7% year-over-year, potentially impacting shareholder returns.
Source: 10-Q Cash Flow
With a debt to equity ratio of 0.86, MDT's leverage could pose risks if interest rates rise.
Source: 10-Q Key Ratios
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Revenue $B | 9.02 $B | 8.29 $B | +8.74% |
Cost of Revenue $B | 3.26 $B | 2.78 $B | +17.34% |
Operating Income $B | 1.46 $B | 1.65 $B | -11.06% |
Net Income $B | 1.14 $B | 1.29 $B | -11.67% |
EPS (Basic) $ | 0.89 $ | 1.01 $ | -11.88% |
EPS (Diluted) $ | 0.89 $ | 1.01 $ | -11.88% |
SG&A Expense $B | 2.96 $B | 2.72 $B | +8.80% |
Answers draw on this SEC filing and the data on this page
Medtronic's Q1 FY2027 results showed double-digit revenue growth and sharply higher earnings, helped by an extra week and broad strength across Cardiovascular, Neuroscience, Medical Surgical, and Diabetes.
Medtronic delivered solid FY2026 results with revenue growing 8.4% to $36.4B and operating cash flow rising 4.1% to $7.3B, though net income growth lagged at 3.0% due to higher operating expenses.
Other companies in Health Care Equipment